Legend Biotech’s Chief Medical Officer, Dr. Mythili Koneru, highlighted the potential of CARVYKTI® to change treatment expectations for relapsed or refractory multiple myeloma, considering the ...

Lorentsen, 35, from Medford, joined several others showing off outfits on the runway, all fashion models for a day and either living with varying degrees of multiple sclerosis themselves, or close ...

Defining Optimal Outcomes in Myeloma. For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear ...

The decision came right after the US regulator also cleared Bristol-Myers Squibb and 2seventy bio’s rival CAR-T Abecma as a third-line therapy for relapsed or refractory multiple myeloma, moving ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...

Towns finished the 2025 postseason with averages of 21.4 points, 11.6 rebounds, 1.3 assists, 0.7 steals and 0.7 blocks in 18 games against the Detroit Pistons, Boston Celtics and Pacers.

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin. Peter Novak; Arlene Williams; Paula Ravin; Omar Zurkiya; Amir Abduljalil; Vera Novak. Disclosures. BMC Neurol. 2012;12(131) ...

The Phase 1b /2 CARTITUDE-1 study (n=97) evaluated CARVYKTI ® for the treatment of heavily pre-treated patients with RRMM. Patients who remained progression free for at least five years (n=32 ...

Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development, commented, "Our proprietary SCS Microinjector ® platform is an established, in-office solution for delivering ...

The global canine arthritis treatment market stands at a valuation of USD 2.50 billion in 2024. Global demand for canine arthritis treatment medications is predicted to rise at a CAGR of 4.20% and ...